Genzyme Corporation’s (GENZ) problems continue with the company recently announcing the discontinuation of the development of its kidney disease drug. Genzyme reported results on its advanced phosphate binder (APB) from a phase II/III study.  Although the candidate met its primary endpoint, results showed that it was not more effective than Renvela, a product that is marketed by Genzyme. Based on these results, the company has decided to discontinue further clinical development of the APB.  Genzyme was looking to develop a product with higher potency that would more effectively bind phosphate, while maintaining all the benefits of Renvela. Renvela is a follow-on product of the company’s kidney disease drug, Renagel. Sales of Renagel/Renvela totaled $677.7 million or 15% of total revenue in 2008.  Renagel and Renvela are phosphate binders for the treatment of hyperphosphatemia. The company was looking to gain approval for the APB before Renagel/Renvela ...

Sprint Nextel (S) has expanded its fourth-generation (4G) wireless broadband network to two more US cities. The third largest US carrier has officially launched commercial services in San Antonio and Austin in Texas. The company’s 4G services now covers about 25 markets in the US, with plans to address more than 120 million people by the end of 2009.
 
Subscribers across the newly launched markets can now enjoy lightning fast mobile broadband experience by paying just $10 per month over their existing 3G wireless data plans. The 4G WiMax network offers up to 10 times faster network speeds than the existing 3G deployments. The download speeds enabled by the 4G WiMax network average 3−6 megabits per second (Mbps), with peak speeds exceeding 10 Mbps.  
 
Sprint offers its 4G service under the “Sprint 4G” brand and leverages the WiMax (a mobile broadband technology) network operated …

Genzyme Corporation’s (GENZ) Lumizyme failed to receive approval from the US Food and Drug Administration (FDA) for the treatment of Pompe disease. The FDA issued a complete response letter (CRL) stating that the agency will not grant approval unless the company addresses the manufacturing issues at its Allston Landing plant in Boston. Genzyme said that it believes that other elements like the Risk Evaluation and Mitigation Strategy (REMS), product label and post-marketing requirements, have been satisfactorily addressed. The FDA’s response on Lumizyme does not come as a surprise. The news regarding the delay in Lumizyme’s approval follows a recent announcement regarding the detection of contamination in vials of five drugs marketed by the company. The agency completed its inspection of the company’s plant last week and has provided Genzyme with a list related to the manufacturing deficiencies found at the plant. The company stated that ...

ArQule Inc (NASDAQ:ARQL) has presented their data at the AACR-NCI-EORTC meeting in Boston which clearly demonstrates the capabilities of Company’s proprietary drug discovery platform to generate a class of small molecules that has significant therapeutic potential. The data reflected the results of the application of the ArQule Kinase Inhibitor Platform (AKIP) to discover and optimize a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR) that are not ATP-competitive and that show potent anti-tumor activity in FGFR-driven cancer models.

ArQule is a biotechnology company which looks after the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™)

...

Enzo Biochem Inc (NYSE:ENZ) has announced that their Vice President of Corporate Development, David Goldberg will speak about Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 Conference which will be held in Boston on Wednesday, November 18, 2009. The Company announced that Enzo Biochem’s EGS21, an orally administered beta glucosylceramide formulation, which is currently undergoing clinical study, has been named one of this year’s top 10 inflammatory and autoimmune projects to watch. The TA Partnership Conference is sponsored by Windhover Information Inc which is world’s leading publisher of science, technical and health information.

Enzo Biochem have already presented their EGS21 clinical studies data recently at the Liver Conference where they showed that the oral administration of EGS21 is safe and appears to be biologically active in patients

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Thursday November 12, 2009

DrStockPick.com Stock Report!

**************************************************************

Healthy Coffee International, Inc. (Pinksheets:HCEI) announced the addition of Mr. Michael Sharp to its team of sales leaders. A native of Florida, Mr. Sharp has over 20 years of combined experience in the network marketing business, representing three Multi Million Dollar MLM companies before moving to Japan. He has also worked as a motivational speaker for two large MLM companies, and was a former trainer with Disney World. His other list of activities include writing and publishing short stories

...

For Immediate Release

Chicago, IL – November 11, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Boston Scientific Corporation (BSX), Johnson & Johnson (JNJ), Medtronic Inc. (MDT), Abbott Laboratories (ABT) and St. Jude Medical Inc. (STJ).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Tuesday’s Analyst Blog:

BSX Settles, Lowers Results

Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic

...

Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic Act by Guidant. The allegations were reported prior to Boston’s acquisition of Guidant in 2006. Boston has recorded the litigation expense in its third quarter of fiscal 2009 results and updated its income statement accordingly. The expense has lowered the company’s GAAP earnings per share by 19 cents into a loss per share of 6 cents in the third quarter of 2009. Adjusted figures remained unaffected by this charge. Boston has also lowered its full fiscal 2009 GAAP earnings per share guidance to a range of 23 to 28 cents, compared to its prior guidance of 43 to 48 cents. The company’s adjusted earnings per share guidance ...

Companies featured in this edition of the newsletter: ACTC, CHIP, CVM, DKAM, ENZ, IWEB, MBCI, MFGD, PHC

Markets rebounded last week, on the strength of upbeat productivity and manufacturing reports that led to solid gains in all of the major indices. Despite news that the unemployment rate had hit its highest levels in 25 years, the Dow managed to end the week up 310 points, gaining 3.2% on the week to close at 10,023, up 14.2% on the year. The Nasdaq posted a gain of 3.3%, closing at 2112 and extending its yearly gains to 34%, while the S&P 500 and Russell 2000 advanced 3.2% and 3.1% respectively on the week to bring their YTD performance to 18.4% and 16.2%.

Several better than expected economic reports provided buying incentive throughout much of the week, as investors managed to shake off the previous week’s negative bias to send indices into positive territory

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday November 4, 2009

DrStockPick.com Stock Report!

**************************************************************

Consorteum Holdings Inc. (OTCBB: CSRH) announced that it has proceeded to launch its consumer stored value rebate card. The consumer rebate card program will offer manufacturers and retailers a new way to process mail-in rebates that ensures increased customer loyalty and decreased overhead costs. Consorteum will work directly with manufactures and retailers to reduce the administration costs associated with mail-in rebate programs while providing a new way to increase consumer awareness. Additional revenue and cost-saving opportunities will be available to all parties through unspent funds remaining on the

...